He Feng, Chen Huacui, Yang Ping, Wu Qianlong, Zhang Tong, Wang Chengxing, Wei Jianchang, Chen Zhuanpeng, Hu He, Li Wanglin, Cao Jie
Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou 510180, China.
Department of Pathology, Interdepartmental Program in Vascular Biology and Therapeutics, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Oncotarget. 2016 Dec 6;7(49):81156-81171. doi: 10.18632/oncotarget.13215.
High levels of angiogenesis, metastasis and chemoresistance are major clinical features of colorectal cancer (CRC), a lethal disease with a high incidence worldwide. Aberrant activation of Wnt/β-catenin pathway contributes to CRC progression. However, little is known about regulatory mechanisms of the β-catenin activity in cancer progression. Here we report that Gankyrin was markedly upregulated in primary tumor tissues from CRC patients and was associated with poor survival. Moreover, we demonstrated that overexpressing Gankyrin promoted, while knockdown of Gankyrin impaired, the aggressive phenotype of proliferation, angiogenesis, chemoresistance and metastasis of CRC cells both in vitro and in vivo. Importantly, we found a unique molecular mechanism of Gankyrin in CRC cells signaling transduction, that regulated the cross-talk between PI3K/Akt and Wnt/β-catenin signaling pathways, sustaining PI3K/GSK-3β/β-catenin signal activation in CRC. Therefore, these findings not only reveal a mechanism that promotes aggressiveness and progression in CRC, but also provide insight into novel molecular targets for antitumor therapy in CRCs.
高水平的血管生成、转移和化疗耐药是结直肠癌(CRC)的主要临床特征,结直肠癌是一种在全球范围内发病率很高的致命疾病。Wnt/β-连环蛋白信号通路的异常激活促进了结直肠癌的进展。然而,关于β-连环蛋白活性在癌症进展中的调控机制知之甚少。在此我们报告,在结直肠癌患者的原发性肿瘤组织中,Gankyrin明显上调,且与较差的生存率相关。此外,我们证明,过表达Gankyrin促进了体外和体内结直肠癌细胞的增殖、血管生成、化疗耐药和转移等侵袭性表型,而敲低Gankyrin则损害了这些表型。重要的是,我们发现了Gankyrin在结直肠癌细胞信号转导中的独特分子机制,即调节PI3K/Akt和Wnt/β-连环蛋白信号通路之间的相互作用,维持结直肠癌中PI3K/GSK-3β/β-连环蛋白信号的激活。因此,这些发现不仅揭示了一种促进结直肠癌侵袭性和进展的机制,也为结直肠癌的抗肿瘤治疗提供了新的分子靶点。